Tonix CEO buys 15,000 TNXP shares in open market

Tonix Pharmaceuticals Holding Corp. Chief Executive Officer Seth Lederman bought 15,000 shares of common stock in an open-market transaction at $14.89 per share through an IRA account.

Accepted by SEC EDGAR 03/18/2026 - 05:03 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Tonix Pharmaceuticals Holding Corp. Chief Executive Officer Seth Lederman bought 15,000 shares of common stock in an open-market transaction at $14.89 per share through an IRA account.

After this purchase, he held 15,001 shares indirectly via the IRA, 4,005 shares directly, and 1 share indirectly through Lederman & Co., where he may be deemed a control person.

Insider Trade Summary

Net Buyer: 15,000 shares

Net Buy 1 txn

Insider LEDERMAN SETH

Role Chief Executive Officer

Bought 15,000 shs ($223K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, $0.001 par value	15,000	$14.89	$223K
Holding	Common Stock, $0.001 par value	--	--	--
Holding	Common Stock, $0.001 par value	--	--	--

Holdings After Transaction: Common Stock, $0.001 par value — 15,001 shares (Indirect, By IRA Account); Common Stock, $0.001 par value — 4,005 shares (Direct); Common Stock, $0.001 par value — 1 shares (Indirect, Lederman & Co.)

Holdings Before and After: Common Stock, $0.001 par value, 1 to 15,001 shares (Indirect, By IRA Account)

Footnotes (1)

1. F1. Reporting person may be deemed a control person of this entity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Tonix Pharmaceuticals (TNXP) report for Seth Lederman?

Tonix Pharmaceuticals reported that CEO Seth Lederman purchased 15,000 shares of common stock in an open-market transaction. The shares were acquired through an IRA account, indicating a personal capital commitment rather than compensation or derivative exercise.

How many Tonix Pharmaceuticals (TNXP) shares did the CEO buy and at what price?

CEO Seth Lederman bought 15,000 Tonix Pharmaceuticals common shares at $14.89 per share. The transaction was an open-market purchase, signaling a deliberate decision to increase his economic exposure to the company’s stock.

What are Seth Lederman’s Tonix Pharmaceuticals (TNXP) holdings after this Form 4?

Following the reported transaction, Seth Lederman held 15,001 Tonix shares indirectly via an IRA, 4,005 shares directly, and 1 share indirectly through Lederman & Co. The filing groups these as his direct and indirect ownership positions.

Was the Tonix Pharmaceuticals (TNXP) CEO transaction a derivative exercise or a simple stock purchase?

The transaction was a simple stock purchase, not a derivative exercise. It is coded as an open-market purchase of common stock, with no options, warrants, or other derivative securities reported in connection with this Form 4.

How is Lederman & Co. related to Seth Lederman’s Tonix (TNXP) holdings?

The filing shows 1 Tonix share held indirectly through Lederman & Co. A footnote states the reporting person may be deemed a control person of this entity, linking that small indirect holding to Seth Lederman.

Does the Tonix Pharmaceuticals (TNXP) Form 4 show both direct and indirect CEO ownership?

Yes. The Form 4 lists 4,005 shares held directly by Seth Lederman and additional indirect holdings: 15,001 shares via an IRA account and 1 share through Lederman & Co., reflecting multiple ownership channels.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LEDERMAN SETH

(Last) (First) (Middle)

C/O TONIX PHARMACEUTICALS HOLDING CORP

200 CONNELL DRIVE, SUITE 3100

(Street)

BERKELEY HEIGHTS NEW JERSEY 07922

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tonix Pharmaceuticals Holding Corp. [ TNXP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.001 par value	03/18/2026		P		15,000	A	$14.89	15,001	I	By IRA Account(1)
Common Stock, $0.001 par value								4,005	D
Common Stock, $0.001 par value								1	I	Lederman & Co.(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reporting person may be deemed a control person of this entity.

	/s/ Seth Lederman	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)